Document Type : Research Paper

Authors

1 Department of Biology, College of Science, University of Anbar, Ramadi, Iraq

2 Biology/ science/ University of Anbar

3 Collage of Medicine, University Of Anbar, Anbar, Iraq

Abstract

Rheumatoid arthritis (RA) is one of the most prevalent chronic, autoimmune diseases of the joints. Although the disease itself is rarely deadly, complications such as disorders of pulmonary and cardiovascular can increase mortality. RA patients can suffer from significant dyslipidemia at various stages of the disease, where the lipid profile may be altered because of the inflammatory activity of the disease. Therefore, the present study aimed to estimate the correlation between lipid profile and markers of inflammation including rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in a sample of Iraqi RA patients. In this study a total of 60 samples were obtained from RA patients and 30 samples from healthy individuals as a control group then samples were tested to measure the levels of lipid and inflammatory markers. The Correlation between lipid profile and inflammatory markers was studied by using Pearson’s correlation (r=−1 to 1). Out of 60 RA patients, 50 were females (83%) and 10 were males (17%) with a mean of age 46.15±10.74 years and a mean disease period of 9.17±6.73 years. The mean of total cholesterol in patients was 194 ± 45.39 mg/dl and the mean of triglycerides was 118 ± 46.78 mg/dl while the mean of HDL, LDL, and VLDL were (46.13±11.14, 125.7±38.63, and 23.59±9.35 mg/dl) respectively in the patients. The mean of RF was (92.04±71.21 IU/ml) while CRP was (5.877±5.92 mg/l) and ESR was (34.17±17.85 mm/h). In conclusion, there was no correlation between inflammatory biomarkers and parameters of lipid profile.
.

Keywords

Main Subjects

[1]        Choy, E. H. S., & Calabrese, L. H. (2018). Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (United Kingdom), 57(11), 1885–1895. https://doi.org/10.1093/rheumatology/kex391
[2]        Bullock, J., Rizvi, S. A. A., Saleh, A. M., Ahmed, S. S., Do, D. P., Ansari, R. A., & Ahmed, J. (2019). Rheumatoid arthritis: A brief overview of the treatment. Medical Principles and Practice, 27(6), 501–507. https://doi.org/10.1159/000493390
[3]        Deane, K. D., & Holers, V. M. (2019). The Natural History of Rheumatoid Arthritis. Clinical Therapeutics, 41(7), 1256–1269. https://doi.org/10.1016/j.clinthera.2019.04.028.
[4]        Drake, D. A. R., Chan, F. T., Briski, E., Bailey, S. A., & Macisaac, H. J. (2018). Extra-articular rheumatoid arthritis. Reumatismo, 73(4), 112–119.
[5]        Gavrilă, B. I., Ciofu, C., & Stoica, V. (2016). Biomarkers in Rheumatoid Arthritis, what is new? Journal of Medicine and Life, 9(2), 144–148.
[6]        Aviña-Zubieta, J. A., Choi, H. K., Sadatsafavi, M., Etminan, M., Esdaile, J. M., & Lacaille, D. (2008). Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Care and Research, 59(12), 1690–1697. https://doi.org/10.1002/art.24092
[7]        Ali, E. T., Jabbar, A. S., & Mohammed, A. N. (2019). A Comparative Study of Interleukin 6, Inflammatory Markers, Ferritin, and Hematological Profile in Rheumatoid Arthritis Patients with Anemia of Chronic Disease and Iron Deficiency Anemia. Anemia, 2019. https://doi.org/10.1155/2019/3457347
[8]        Robertson, J., Peters, M. J., McInnes, I. B., & Sattar, N. (2013). Changes in lipid levels with inflammation and therapy in RA: A maturing paradigm. Nature Reviews Rheumatology, 9(9), 513–523. https://doi.org/10.1038/nrrheum.2013.91
[9]        van Sijl, A. M., Peters, M. J. L., Knol, D. L., de Vet, R. H. C., Sattar, N., Dijkmans, B. A. C., Smulders, Y. M., & Nurmohamed, M. T. (2011). The Effect of TNF-alpha Blocking Therapy on Lipid Levels in Rheumatoid Arthritis: A Meta-Analysis. Seminars in Arthritis and Rheumatism, 41(3), 393–400. https://doi.org/10.1016/j.semarthrit.2011.04.003
[10] Wan, X., Wang, W., Liu, J., & Tong, T. (2014). Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology, 14(1), 1–13. https://doi.org/10.1186/1471-2288-14-135
 [11] DeBose-Boyd, R. A. (2018). Significance and regulation of lipid metabolism. Seminars in Cell and Developmental Biology, 81, 97. https://doi.org/10.1016/j.semcdb.2017.12.003
[12] Venetsanopoulou, A. I., Pelechas, E., Voulgari, P. V., & Drosos, A. A. (2020). The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatology International, 40(8), 1181–1191. https://doi.org/10.1007/s00296-020-04616-2
[13] Naseri, H., Zarrin, R., Ayremlou, P., Aghdashi, M. A., & Seyedmardani, S. (2020). Evaluating the relationship between dietary intake with inflammatory factors, lipid profile and clinical symptoms in patients with rheumatoid arthritis. Clinical Nutrition ESPEN, 40(xxxx), 138–143. https://doi.org/10.1016/j.clnesp.2020.09.215
[14] Svenson, K. L. G., Lithell, H., Hällgren, R., Selinus, I., & Vessby, B. (1987). Serum Lipoprotein in Active Rheumatoid Arthritis and Other Chronic Inflammatory Arthritides: I. Relativity to Inflammatory Activity. Archives of Internal Medicine, 147(11), 1912–1916. https://doi.org/10.1001/archinte.1987.00370110040005
[15] Lazarevic, M. B., Vitic, J., Mladenovic, V., Lee Myones, B., Skosey, J. L., & Swedler, W. I. (1992). Dyslipoproteinemia in the course of active rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 22(3), 172–180. https://doi.org/10.1016/0049-0172(92)90017-8
[16] Rantapaa-dahlqvist, S., Wallberg-jonsson, S., & Dahlen, G. (1991). Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Cv, 366–368.
[17] Curtis, J. R., John, A., & Baser, O. (2012). Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care and Research, 64(9), 1282–1291. https://doi.org/10.1002/acr.21693
[18] Vinapamula, K. S., Manohar, S. M., Bitla, A. R., Kanduri, R., Bhattaram, S. K., & Pemmaraju, S. R. V. L. N. (2013). Evaluation of dyslipidaemia in patients with rheumatoid arthritis in South Indian population. Indian Journal of Rheumatology, 8(4), 155–160. https://doi.org/10.1016/j.injr.2013.06.006
[19] van den Oever, I. A. M., Baniaamam, M., Simsek, S., Raterman, H. G., van Denderen, J. C., van Eijk, I. C., Peters, M. J. L., van der Horst-Bruinsma, I. E., Smulders, Y. M., & Nurmohamed, M. T. (2021). The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. Rheumatology International, 41(2), 319–328. https://doi.org/10.1007/s00296-020-04666-6
[20]      Dursunoǧlu, D., Evrengül, H., Polat, B., Tanriverdi, H., Çobankara, V., Kaftan, A., & Kiliç, M. (2005). Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation. Rheumatology International, 25(4), 241–245. https://doi.org/10.1007/s00296-004-0438-0
[21] Yoo, W.-H. (2004). Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. The Journal of Rheumatology, 31(9), 1746 LP – 1753. http://www.jrheum.org/content/31/9/1746.abstract
[22] Chen, D.-Y., Chen, Y.-M., Hsieh, T.-Y., Hsieh, C.-W., Lin, C.-C., & Lan, J.-L. (2015). Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Research & Therapy, 17, 1–13.
[23]      Mahdi, E. A., Mohamed, L. A., & Hadi, M. A. (2012). The Relationship Between Lipid Profile and Inflammatory Markers. Iraqi National Journal of Chemistry, 47, 391– 400.